Výsledky vyhledávání - "Melissa Pozotrigo"

Abstract P4-01-36: Real World Data for Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases

Autor: Andrew Toler, Laura R. Bobolts, Mark Mangurian, Melissa Pozotrigo, Corey Wise, Hiywete Solomon, Nicole Hartung, Rory Makielski, Shika Marur, Meera Ravindranathan, Shanthi Marur

Publikováno v: Cancer Research. 83:P4-01

Background: Trastuzumab deruxtecan (T-DXd) improves outcomes in HER2-positive metastatic breast cancer (MBC) patients, including patients with previously treated stable brain metastases (BMs). Our objective was to examine the characteristics of HER2-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1504256fa88beb2cb54a7810f1a2acea
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-36

Zobrazit plný text záznamu

Abstract P4-01-40: Real World Data with Off-Label Insurance Approval of Trastuzumab Deruxtecan in Metastatic Breast Cancer

Autor: Laura R. Bobolts, Mark Mangurian, Shanthi Marur, Corey Wise, Melissa Pozotrigo, Hiywete Solomon, Nicole Hartung, Meera Ravindranathan, Rory Makielski, Shika Marur, Andrew Toler

Publikováno v: Cancer Research. 83:P4-01

Background: Trastuzumab deruxtecan (T-DXd) improves outcomes in HER2-positive, and recently in HER2-low (IHC 1+ or IHC 2+/ISH-) previously treated metastatic breast cancer (MBC) patients. OncoHealth is a digital health care company that leverages man

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ebf3630274f80612f3f195e50a530fc1
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-40

Zobrazit plný text záznamu

Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience

Autor: Meier Hsu, Susan K. Seo, Nina Cohen, Sherry Mathew, Jennifer Thackray, Michelle L Kussin, Brian Seyboth, Dazhi Liu, Melissa Pozotrigo, Shirley Qiong Yan

Publikováno v: Journal of the Pediatric Infectious Diseases Society. 6:e149-e151

Limited data on optimal posaconazole dosing strategies for pediatric patients exist. In this study, we found that the median initial dose in patients who achieved a posaconazole plasma concentration of 0.7 μg/mL was 22.8 mg/kg per day whereas the me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::723c3704f14907fb4cc38314426aec24
https://doi.org/10.1093/jpids/pix058

Zobrazit plný text záznamu

Antimicrobial stewardship efforts to manage a pentamidine shortage

Autor: Alla Paskovaty, Melissa Pozotrigo, Priti Patel, Marie Ryan, Charles D. Lucarelli, Jennifer Thackray, Brian Seyboth, Nina Orsini, Susan K. Seo

Publikováno v: American Journal of Health-System Pharmacy. 71:2014-2018

The number of drug shortages quadrupled from 2004, with 58 shortages, to 267 in 2011.[1][1] Eighty percent of the 127 studied shortages in 2010–11 involved sterile injections, and the leading causes for the reported sterile injection shortages incl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f776ed7d3efa81034d98bd359d37f608
https://doi.org/10.2146/ajhp130661

Zobrazit plný text záznamu

Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center

Autor: Nelly G. Adel, L Reich, Melissa Pozotrigo, Elyn Riedel, Hani Hassoun, Nikoletta Lendvai, Xiaoshe Chen, Alexander M. Lesokhin, Sergio Giralt, David J. Chung, Danielle Chimento, Raymond L. Comenzo, Heather Landau

Publikováno v: Bone Marrow Transplantation. 48:1033-1039

Thalidomide, lenalidomide and bortezomib have increasingly been incorporated in first-line induction therapies for multiple myeloma. Concerns regarding the impact of these agents, especially lenalidomide, on stem cell mobilization prompted us to re-e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7a296d3a886bb5c79bfaa1752808aac
https://doi.org/10.1038/bmt.2012.281

Zobrazit plný text záznamu

Fosaprepitant use in children and adolescents at Memorial Sloan Kettering Cancer Center

Autor: Michelle L Kussin, Shirley Qiong Yan, Krisoula Horiates, Dazhi Liu, Jennifer Thackray, Brian Seyboth, Shakeel Modak, Melissa Pozotrigo, Sherry Mathew

Publikováno v: Journal of Clinical Oncology. 35:10575-10575

10575 Background: Recent NCCN guidelines recommend the addition of a neurokinin-1(NK1) receptor antagonist (e.g. fosaprepitant) to the serotonin 5-hydroxytryptamine type 3 (5-HT3) receptor antagonist-corticosteroid combination for controlling both ac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fe3ee64a399e553b9edee5c125742563
https://doi.org/10.1200/jco.2017.35.15_suppl.10575

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání